Deputy Associate Director of DEIA/Associate Professor of Immunology and Microbiology
University of Colorado Cancer Center/University of Colorado Anschutz Medical Campus
Denver, Colorado, United States
Dr. Curtis J. Henry is the Deputy Associate Director of Diverisity, Equity, Inclusion, and Access at the University of Colorado Cancer Center, an Associate Professor of Immunology & Microbiology at the University of Colorado Anschutz Medical Campus, and The Margaret Turley Grohne Chair in Translational Cancer Research.
Dr. Henry received his undergraduate degrees in Molecular Biology and Chemistry from Florida Agricultural and Mechanical University (2003), followed by his doctorate degree in Immunology from Wake Forest University School of Medicine (2008) under the tutelage of Dr. Elizabeth Hiltbold-Schwartz. Dr. Henry then completed his postdoctoral fellowship (2008-2012) and was promoted to Research Instructor (2012-2016) under the guidance of Dr. James DeGregori at the University of Colorado Anschutz Medical Campus. During his career, Dr. Henry has received several prestigious grants including an NCI-funded K01, an American Cancer Society Junior Faculty Achievement Award, an Aflac Pilot Grant, and the Mark Foundation for Cancer Research ASPIRE Award. Dr. Henry has also been listed as the first or senior author on numerous manuscripts published in highly-cited journals such as Nature Communications, Cancer Research, the Proceedings of the National Academy of Sciences of the United States of America, and the Journal of Clinical Investigation. In addition to Dr. Henry’s publications, several provisional patents have been awarded to his team and collaborators for their research endeavors.
Research conducted in the Henry laboratory focuses on understanding how cancer-associated comorbidities promote cancer with the goal of improving the efficacy of chemo- and immune-based therapies in patients falling within high-risk demographics.
Disclosure information not submitted.
Adipocyte-secreted interleukin-9 Promotes B Cell Acute Lymphoblastic Leukemia Progression
Friday, June 21, 2024
3:20 PM - 3:45 PM PT
